NextCell Pharma AB (65G) Price & Analysis

0 Followers

65G Stock Chart & Stats

€0.05

>-€0.01(-2.19%)

At close: Jan 08 4:00 PM EST

€0.05

>-€0.01(-2.19%)

Day’s Range― - ―

52-Week Range€0.05 - €0.17

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€11.48M

Enterprise Value€107.45

Total Cash (Recent Filing)€32.33M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.26

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding126,392,960

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.04

Revenue Forecast (FY)€1.10M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt materially reduces financial risk and interest obligations, giving the company strategic flexibility to prioritize R&D and clinical timelines. For a capital-intensive biotech, low leverage improves optionality for funding choices and lowers insolvency risk over the medium term.

Multi-year Revenue GrowthSustained top-line growth over multiple years indicates expanding commercial traction in cell therapies and services. Rising revenue supports scale economies in manufacturing and cell banking, improving the potential for future margin leverage as fixed costs are allocated across larger sales volumes.

Integrated Cell Therapy CapabilitiesOwning both therapeutic programs (MSC/ProTrans) and cell banking/manufacturing creates a vertically integrated model and specialized know-how. These capabilities raise barriers to entry, enable recurring service revenue, and help control quality and regulatory process—durable competitive advantages in cell therapy.

Bears Say

High Cash Burn And Negative FCFPersistent large negative operating and free cash flows signal substantial ongoing cash burn, requiring frequent external financing. This chronic cash deficit increases dilution risk, limits ability to self-fund clinical development or scale manufacturing, and constrains long-term strategic flexibility.

Sustained Unprofitability And Negative MarginsConsistent negative gross profit and large net losses show the business has not yet reached sustainable unit economics. Without structural margin improvement—via cost reductions, pricing power, or higher-margin revenue—revenue growth alone may not deliver durable profitability for shareholders.

Eroding Equity And Dilution RiskMaterial decline in equity over recent years reflects cumulative losses and likely capital raises, weakening the balance-sheet cushion. Reduced equity increases vulnerability to future dilution when raising funds, and can constrain ability to pursue partnerships or strategic investments without further shareholder dilution.

65G FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was €0.05 and its highest was €0.17 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is €11.48M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is Aug 27, 2026 which is in 12 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on May 28, 2026. The company reported -€0.008 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 126,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -€0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in DE:65G

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.